Bright Minds Biosciences (DRUG) Q3 2025 earnings summary

Executive summary

• Net loss of $8.1M for the nine months ended June 30, 2025, compared to $2.0M loss for the same period last year, driven by increased R&D activity and related expenses.

• Cash and cash equivalents rose to $51.4M as of June 30, 2025, following a $35M (US) private placement in November 2024.

• Focus remains on advancing clinical-stage therapeutics for CNS disorders, with BMB-101 in Phase 2 trials for drug-resistant epilepsies.

Financial highlights

• Cash and cash equivalents increased from $5.7M at September 30, 2024, to $51.4M at June 30, 2025.

• Net and comprehensive loss for the nine months ended June 30, 2025, was $8.1M, up from $2.0M loss year-over-year.

• Research and development expenses for the nine months ended June 30, 2025, totaled $6.3M, up from $764K for the same period last year.

• Share-based compensation expense for the nine months ended June 30, 2025, was $2.1M, compared to $630K in the prior year.

Outlook and guidance

• Current cash resources are expected to fund operations and R&D for at least the next twelve months.

• Management continues to seek additional capital through equity financings and strategic partnerships.

• Ongoing focus on advancing BMB-101 through Phase 2 clinical trials and expanding the pipeline for CNS and neuropsychiatric indications.